Slobod KS - Search Results

1

HIV vaccine rationale, design and testing.

Slobod KS, Coleclough C, Bonsignori M, Brown SA, Zhan X, Surman S, Zirkel A, Jones BG, Sealy RE, Stambas J, Brown B, Lockey TD, Freiden PJ, Doherty PC, Blanchard JL, Martin LN, Hurwitz JL. Slobod KS, et al. Curr HIV Res. 2005 Apr;3(2):107-12. doi: 10.2174/1570162053506928. Curr HIV Res. 2005. PMID: 15853717 Review.

2

Clustering of Th cell epitopes on exposed regions of HIV envelope despite defects in antibody activity.

Brown SA, Stambas J, Zhan X, Slobod KS, Coleclough C, Zirkel A, Surman S, White SW, Doherty PC, Hurwitz JL. Brown SA, et al. Among authors: slobod ks. J Immunol. 2003 Oct 15;171(8):4140-8. doi: 10.4049/jimmunol.171.8.4140. J Immunol. 2003. PMID: 14530336

3

Minor components of a multi-envelope HIV vaccine are recognized by type-specific T-helper cells.

Zhan X, Slobod KS, Surman S, Brown SA, Coleclough C, Hurwitz JL. Zhan X, et al. Among authors: slobod ks. Vaccine. 2004 Mar 12;22(9-10):1206-13. doi: 10.1016/j.vaccine.2003.09.028. Vaccine. 2004. PMID: 15003649

4

T cell epitope "hotspots" on the HIV Type 1 gp120 envelope protein overlap with tryptic fragments displayed by mass spectrometry.

Brown SA, Lockey TD, Slaughter C, Slobod KS, Surman S, Zirkel A, Mishra A, Pagala VR, Coleclough C, Doherty PC, Hurwitz JL. Brown SA, et al. Among authors: slobod ks. AIDS Res Hum Retroviruses. 2005 Feb;21(2):165-70. doi: 10.1089/aid.2005.21.165. AIDS Res Hum Retroviruses. 2005. PMID: 15725756

5

CD8+ T-cells: are they sufficient to prevent, contain or eradicate HIV-1 infection?

Brown SA, Hurwitz JL, Zhan X, Doherty PC, Slobod KS. Brown SA, et al. Among authors: slobod ks. Curr Drug Targets Infect Disord. 2005 Jun;5(2):113-9. doi: 10.2174/1568005054201571. Curr Drug Targets Infect Disord. 2005. PMID: 15975017 Review.

6

Application of the polyvalent approach to HIV-1 vaccine development.

Hurwitz JL, Slobod KS, Lockey TD, Wang S, Chou TH, Lu S. Hurwitz JL, et al. Among authors: slobod ks. Curr Drug Targets Infect Disord. 2005 Jun;5(2):143-56. doi: 10.2174/1568005054201517. Curr Drug Targets Infect Disord. 2005. PMID: 15975020 Review.

7

HIV vaccines: brief review and discussion of future directions.

Slobod KS, Bonsignori M, Brown SA, Zhan X, Stambas J, Hurwitz JL. Slobod KS, et al. Expert Rev Vaccines. 2005 Jun;4(3):305-13. doi: 10.1586/14760584.4.3.305. Expert Rev Vaccines. 2005. PMID: 16026246 Review.

8

Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV.

Zhan X, Martin LN, Slobod KS, Coleclough C, Lockey TD, Brown SA, Stambas J, Bonsignori M, Sealy RE, Blanchard JL, Hurwitz JL. Zhan X, et al. Among authors: slobod ks. Vaccine. 2005 Nov 16;23(46-47):5306-20. doi: 10.1016/j.vaccine.2005.07.008. Epub 2005 Jul 20. Vaccine. 2005. PMID: 16095768

9

HIV-1 vaccine development: tackling virus diversity with a multi-envelope cocktail.

Hurwitz JL, Zhan X, Brown SA, Bonsignori M, Stambas J, Lockey TD, Sealy R, Surman S, Freiden P, Jones B, Martin L, Blanchard J, Slobod KS. Hurwitz JL, et al. Among authors: slobod ks. Front Biosci. 2008 Jan 1;13:609-20. doi: 10.2741/2706. Front Biosci. 2008. PMID: 17981574 Review.

10

First phase I clinical trial of an HIV-1 subtype D gp140 envelope protein vaccine: immune activity induced in all study participants.

Hurwitz JL, Lockey TD, Jones B, Freiden P, Sealy R, Coleman J, Howlett N, Branum K, Slobod KS. Hurwitz JL, et al. Among authors: slobod ks. AIDS. 2008 Jan 2;22(1):149-51. doi: 10.1097/QAD.0b013e3282f174ed. AIDS. 2008. PMID: 18090404 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

75 results

Search Page